drugset

drugset / Trial / NCT00632385

Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy

NCT00632385 ↗

Phase 4 Completed 127 enrolled Viatris Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To assess the efficacy and safety of eletriptan for migraine headaches in subjects who were not satisfied with rizatriptan therapy

Timeline

Start: 2003-01
Primary completion: —
Completion: 2003-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Eletriptan	Small molecule	40 mg	Oral

Indications